Celgene Corporation (CELG) Position Cut by MD Sass Investors Services Inc.
MD Sass Investors Services Inc. decreased its position in shares of Celgene Corporation (NASDAQ:CELG) by 14.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 644,279 shares of the biopharmaceutical company’s stock after selling 109,250 shares during the period. Celgene Corporation comprises 5.5% of MD Sass Investors Services Inc.’s investment portfolio, making the stock its biggest position. MD Sass Investors Services Inc. owned approximately 0.08% of Celgene Corporation worth $83,673,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Thompson Davis & CO. Inc. lifted its stake in Celgene Corporation by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 43 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. acquired a new position in Celgene Corporation during the 1st quarter worth about $118,000. Motco lifted its stake in Celgene Corporation by 19.3% during the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 159 shares in the last quarter. Acropolis Investment Management LLC purchased a new stake in Celgene Corporation during the 2nd quarter worth about $144,000. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. increased its holdings in Celgene Corporation by 47.5% during the 1st quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 380 shares during the period. 79.48% of the stock is currently owned by hedge funds and other institutional investors.
CELG has been the topic of several recent research reports. BMO Capital Markets upped their price target on Celgene Corporation from $148.00 to $155.00 and gave the stock an “outperform” rating in a report on Friday. Leerink Swann restated an “outperform” rating and set a $160.00 price target (up previously from $150.00) on shares of Celgene Corporation in a report on Friday, July 28th. Oppenheimer Holdings, Inc. restated a “buy” rating and set a $170.00 price target on shares of Celgene Corporation in a report on Friday, October 20th. Vetr upgraded Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $144.39 price target on the stock in a report on Monday, October 23rd. Finally, Cann restated a “buy” rating on shares of Celgene Corporation in a report on Thursday, October 26th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have assigned a buy rating and two have assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $139.87.
TRADEMARK VIOLATION WARNING: “Celgene Corporation (CELG) Position Cut by MD Sass Investors Services Inc.” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/11/21/celgene-corporation-celg-position-cut-by-md-sass-investors-services-inc.html.
Celgene Corporation (NASDAQ CELG) opened at $103.15 on Tuesday. Celgene Corporation has a one year low of $94.55 and a one year high of $147.17. The firm has a market capitalization of $81,210.00, a P/E ratio of 16.27, a P/E/G ratio of 0.80 and a beta of 1.79. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31.
Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the consensus estimate of $1.87 by $0.04. Celgene Corporation had a return on equity of 63.80% and a net margin of 27.36%. The firm had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same period last year, the business posted $1.58 EPS. Celgene Corporation’s quarterly revenue was up 10.2% on a year-over-year basis. equities analysts predict that Celgene Corporation will post 6.67 earnings per share for the current fiscal year.
In related news, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the transaction, the insider now directly owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gilla Kaplan sold 9,250 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the completion of the transaction, the director now directly owns 85,551 shares of the company’s stock, valued at $12,110,599.56. The disclosure for this sale can be found here. Insiders sold a total of 20,227 shares of company stock valued at $2,843,956 over the last ninety days. 0.95% of the stock is currently owned by company insiders.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.